Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 19-26

  Tetef, Merry L ^a   Margolin, Kim A ^a   Doroshow, James H ^a   Akman, Steven ^a   Leong, Lucille A ^a   Morgan, Robert J ^a   Raschko, James W ^a   Slatkin, Neil ^a   Somlo, George ^a   Longmate, Jeffrey A ^a   Carroll, Mary I ^a   Newman, Edward M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Leptomeningeal carcinomatosis; Methotrexate

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0033949267     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000118     Document Type: Article

References (24)

1. 1. Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG (1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 3: 485
2. 2. Blay J-Y, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, Bouabdallah R, Coiffier B, Wagner J-P, Mevel AL, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864
3. 3. Bleyer WA, Drake JC, Chabner BA (1973) Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289: 770
4. 4. Chamberlain MC, Khatibi S, Kim SC, Howell SB, Chatelut E, Kim S (1993) Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50: 261
5. 5. Ettinger LJ, Chervinsky DS, Freeman AI, Creaven PJ (1982) Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer 50: 1676
6. 6. Evans WE, Hutson PR, Stewart CF, Cairness DA, Bowman WP, Rivera G, Crom WR (1983) Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 33: 301
7. 7. Glantz M, Phuphanich S, White CA, Jaeckle KA, Recht L, Allen J, Swinnen L, Chocair A, Aikens R, Greenberg HS, New P, Brunson C, Gertler S, Maria B, Chamberlain M (1996) Treatment of leptomeningeal metastases with intra-CSF DepoFoam encapsulated cytarabine. Proc Am Soc Clin Oncol 15: 160
8. 8. Glantz MJ, Cole BF, Recht L, Akerley W, Mills S, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998) High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16: 1561
9. 9. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11: 561
10. 10. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA (1982) Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 73: 413
11. 11. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singher LJ, Ettinger LJ, Gillepsie A, Sam J, Poplack DG (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49: 736
12. 12. Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5: 1655
13. 13. Hryniuk WM, Bertino JR (1969) Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 48: 2140
14. 14. Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73: 13
15. 15. Mehta BM, Glass JP, Shapiro WR (1983) Serum and cerebrospinal fluid distribution of 5-methyl tetrahydrofolate after intravenous calcium leucovorin and intra-ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res 43: 435
16. 16. Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack D, Bleyer A (1985) Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse. J Clin Oncol 3: 19
17. 17. Newman EM, Villacorte DG, Testi AM, Krance RA, Harris MB, Ravindranath Y, Pinkel D (1990) Biochemical interactions between methotrexate and 1-β-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study. Cancer Chemother Pharmacol 27: 60
18. 18. Olson ME, Chernik NL, Posner JB (1974) Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol 30: 122
19. 19. Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar injections. N Engl J Med 293: 161
20. 20. Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E3, Canellos GP (1977) High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin's lymphoma including CNS involvement. Blood 50: 1039
21. 21. Ushio Y, Shimizu K, Aragaki Y, Arita N, Hayakawa T, Mogami H (1981) Alteration of blood-CSF barrier by tumor invasion into the meninges. J Neurosurg 55: 445
22. 22. Wasserstrom WR, Glass P, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49: 759
23. 23. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR (1982) Treatment of meningeal carcinomatosis in breast cancer. Cancer 49: 219
24. 24. Zaharko DS, Dedrick RL (1984) Pharmacokinetics of methotrexate in animals and man. In: Sirotnak FM, Burchall JJ, Ensminger WD, Montgomery JA (eds) Folate antagonists as therapeutic agents, Academic Press, Orlando, p 97